TEDA Unveils Plan For Biopharmaceutical Industry
This article was originally published in PharmAsia News
The Tianjin Economic-Technological Development Area recently unveiled its plans for the biopharmaceutical industry. By 2015, it aims to establish a biopharmaceutical industry worth RMB 50 billion, attracting more than 40 large manufacturing enterprises and targeting export rates of 30 percent. TEDA seeks to be an important Asia-Pacific pharmaceutical R&D and manufacturing hub with links to international contract research and manufacturing organizations. A biopharmaceutical industry cluster will be set up to integrate pharmaceutical MNCs, local leading companies and small- and medium-sized innovative enterprises. TEDA aims to develop its own unique characteristics in the CRO, CMO and medical device domains, nurture a core batch of leading pioneers for Tianjin's biopharmaceutical industry and make breakthroughs in new drug creation. (Click here for more - Chinese Language)
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.